Stocks Health care AVXL
NASDAQ · Health careAnavex Life Sciences Corp. (AVXL)
It posted a net loss of $13M. At June 30, 2026 it held $118.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 28, 2026.
Key facts about Anavex Life Sciences Corp.
- Net worth
- Anavex Life Sciences Corp. has a market value (market cap) of $113.1M at the latest share price, and shareholders' equity of $112.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $39M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 28, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Anavex Life Sciences Corp. does
Anavex Life Sciences Corp. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AVXL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$46.4M | -$0.54 | n/a |
| 2024 | n/a | -$43M | -$0.52 | n/a |
| 2023 | n/a | -$47.5M | -$0.60 | n/a |
| 2022 | n/a | -$48M | -$0.62 | n/a |
| 2021 | n/a | -$37.9M | -$0.54 | n/a |
| 2020 | n/a | -$26.3M | -$0.45 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Anavex Life Sciences Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- November 2, 2026
- October 20, 2026Other event 8-K
- October 15, 2026Other event 8-K
- September 28, 2026Change in control8-KAnavex stockholders elected all company director nominees in a contested vote, which triggered accelerated vesting of unvested equity awards.
- September 21, 2026Form DFAN14A filing DFAN14A
- September 18, 2026Form DFAN14A filing DFAN14A
- September 17, 2026Form DFAN14A filing DFAN14A
- September 15, 2026Additional proxy material DEFA14A
- September 15, 2026Form DFAN14A filing DFAN14A
Insider trades
What the people running Anavex Life Sciences Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns AVXL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 5.03% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 179 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 8,055,628 | +446,010 |
| Vanguard Capital Management LLC | 4,054,589 | +190,639 |
| Two Sigma Investments, LP | 3,046,538 | -201,350 |
| Geode Capital Management, LLC | 2,407,473 | +219,198 |
| State Street Corp | 1,922,770 | -2,589,258 |
| Federated Hermes, Inc. | 1,071,809 | +539,557 |
| Aqr Capital Management LLC | 963,014 | +206,222 |
| Vanguard Portfolio Management LLC | 948,633 | +165,485 |
| Summit Financial, LLC | 909,430 | -31,025 |
| Goldman Sachs Group Inc | 890,634 | +86,199 |
| Marshall Wace, Llp | 889,523 | +470,026 |
| Northern Trust Corp | 784,494 | +59,307 |
| Barclays PLC | 754,226 | +215,949 |
| Charles Schwab Investment Management Inc | 734,795 | -21,763 |
| Bank of America Corp | 654,295 | -208,855 |
| Vanguard Fiduciary Trust Co | 621,451 | -25,718 |
| UBS Group AG | 620,374 | +50,418 |
| Private Advisor Group, LLC | 504,000 | +4,300 |
| LPL Financial LLC | 406,109 | -12,531 |
| Stifel Financial Corp | 332,597 | +95,793 |
Insiders
Questions about AVXL
What does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp. is a company in the Health care sector, listed on NASDAQ as AVXL. Its shares trade on NASDAQ under the ticker AVXL.
What is Anavex Life Sciences Corp.'s net worth?
Anavex Life Sciences Corp. has a market value (market cap) of $113.1M at the latest share price, and shareholders' equity of $112.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Anavex Life Sciences Corp. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $13M.
When did Anavex Life Sciences Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
Similar companies
Compare AVXL with
Follow AVXL
Get an email when Anavex Life Sciences Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Anavex Life Sciences Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.